EGFR as a Target: Rationale for Therapy
- 28 February 2006
- journal article
- review article
- Published by Elsevier in Seminars in Oncology Nursing
- Vol. 22, 5-9
- https://doi.org/10.1016/j.soncn.2006.01.010
Abstract
No abstract availableKeywords
This publication has 23 references indexed in Scilit:
- Pharmacological background of EGFR targetingAnnals of Oncology, 2004
- Monoclonal antibodies as therapeutic agents for cancerThe Lancet Oncology, 2004
- Phase II Trial of Cetuximab in Patients With Refractory Colorectal Cancer That Expresses the Epidermal Growth Factor ReceptorJournal of Clinical Oncology, 2004
- Gefitinib in Combination With Gemcitabine and Cisplatin in Advanced Non–Small-Cell Lung Cancer: A Phase III Trial—INTACT 1Journal of Clinical Oncology, 2004
- Multi-Institutional Randomized Phase II Trial of Gefitinib for Previously Treated Patients With Advanced Non–Small-Cell Lung CancerJournal of Clinical Oncology, 2003
- Why the Epidermal Growth Factor Receptor? The Rationale for Cancer TherapyThe Oncologist, 2002
- Monoclonal antibodies to target epidermal growth factor receptor–positive tumorsCancer, 2002
- The HER‐2/ neu Oncogene in Breast Cancer: Prognostic Factor, Predictive Factor, and Target for TherapyThe International Journal of Cell Cloning, 1998
- A mouse/human chimeric anti-(ganglioside GD3) antibody with enhanced antitumor activitiesCancer Immunology, Immunotherapy, 1993
- The EGF Receptor System as a Target for Antitumor TherapyCancer Investigation, 1991